Urokinase-type plasminogen activator system and human cationic antimicrobial protein 18 in serum and induced sputum of patients with chronic obstructive pulmonary disease

Respirology

Volumn 15, Issue 6, 2010, Pages 939-946

  Jiang, Yuanyuan ^a   Xiao, Wei ^a   Zhang, Yi ^a   Xing, Ying ^b  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

chronic obstructive pulmonary disease; human cationic antimicrobial protein 18; induced sputum; innate immune biomarker; urokinase type plasminogen activator system

Indexed keywords

HUMAN CATIONIC ANTIMICROBIAL PROTEIN 18; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

ADULT; ARTICLE; CELL MEMBRANE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TOLERANCE; FEMALE; FLOW CYTOMETRY; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HUMAN; INNATE IMMUNITY; MACROPHAGE; MALE; MEMBRANE BINDING; NEUTROPHIL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUESTIONNAIRE; RESPIRATORY AIRFLOW; SMOKING; SPUTUM ANALYSIS; SPUTUM LEVEL;

ANTIMICROBIAL CATIONIC PEPTIDES; BRONCHODILATOR AGENTS; EXERCISE TOLERANCE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNITY, INNATE; MACROPHAGES; MALE; MIDDLE AGED; NEUTROPHILS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SEVERITY OF ILLNESS INDEX; SMOKING; SPUTUM; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77954923270     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2010.01799.x     Document Type: Article

References (35)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997 349 : 1498 1504.
2. Rabe KF, Hurd S, Anzueto A et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007 176 : 532 555.
3. Hubbard RC, Fells G, Gadek J et al. Neutrophil accumulation in the lung in alpha 1-antitrypsin deficiency. Spontaneous release of leukotriene B4 by alveolar macrophages. J. Clin. Invest. 1991 88 : 891 897.
4. Nadel JA. Role of neutrophil elastase in hypersecretion during COPD exacerbations, and proposed therapies. Chest 2000 117 : 386S 9S.
5. Gompertz S, O'Brien C, Bayley DL et al. Changes in bronchial inflammation during acute exacerbations of chronic bronchitis. Eur. Respir. J. 2001 17 : 1112 1119.
6. Tetley TD. Macrophages and the pathogenesis of COPD. Chest 2002 121 : 156S 9S.
7. Schleimer RP. Innate immune responses and chronic obstructive pulmonary disease: 'Terminator' or 'Terminator 2'? Proc. Am. Thorac. Soc. 2005 2 : 342 346.
8. D'Hulst AI, Maes T, Bracke KR et al. Cigarette smoke-induced pulmonary emphysema in scid-mice. Is the acquired immune system required? Respir. Res. 2005 6 : 147.
9. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J. Clin. Invest. 1991 88 : 1067 1072.
10. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb. Haemost. 2001 86 : 324 333.
11. Lijnen HR. Elements of the fibrinolytic system. Ann. N. Y. Acad. Sci. 2001 936 : 226 236.
12. Chapman HA. Disorders of lung matrix remodeling. J. Clin. Invest. 2004 113 : 148 157.
13. American Thoracic Society. Standardization of spirometry, 1994 update. Am. J. Respir. Crit. Care Med. 1995 152 : 1107 1136.
14. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001 56 : 880 887.
15. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002 166 : 111 117.
16. Drapkin PT, O'Riordan CR, Yi SM et al. Targeting the urokinase plasminogen activator receptor enhances gene transfer to human airway epithelia. J. Clin. Invest. 2000 105 : 589 596.
17. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 2000 12 : 613 620.
18. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol. 2004 25 : 450 455.
19. Rijneveld AW, Levi M, Florquin S et al. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J. Immunol. 2002 168 : 3507 3511.
20. Gyetko MR, Sud S, Chen GH et al. Urokinase-type plasminogen activator is required for the generation of a type 1 immune response to pulmonary Cryptococcus neoformans infection. J. Immunol. 2002 168 : 801 809.
21. Woolhouse IS, Bayley DL, Stockley RA. Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax 2002 57 : 667 671.
22. Sorensen O, Arnljots K, Cowland JB et al. The human antibacterial cathelicidin, hCAP-18, is synthesized in myelocytes and metamyelocytes and localized to specific granules in neutrophils. Blood 1997 90 : 2796 2803.
23. Frohm Nilsson M, Sandstedt B, Sorensen O et al. The human cationic antimicrobial protein (hCAP18), a peptide antibiotic, is widely expressed in human squamous epithelia and colocalizes with interleukin-6. Infect. Immun. 1999 67 : 2561 2566.
24. Agerberth B, Charo J, Werr J et al. The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations. Blood 2000 96 : 3086 3093.
25. Putsep K, Carlsson G, Boman HG et al. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 2002 360 : 1144 1149.
26. Nagaoka I, Hirota S, Niyonsaba F et al. Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J. Immunol. 2001 167 : 3329 3338.
27. De Smet K, Contreras R. Human antimicrobial peptides: defensins, cathelicidins and histatins. Biotechnol. Lett. 2005 27 : 1337 1347.
28. Yang D, Chen Q, Schmidt AP et al. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med. 2000 192 : 1069 1074.
29. Elssner A, Duncan M, Gavrilin M et al. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J. Immunol. 2004 172 : 4987 4994.
30. Koczulla R, von Degenfeld G, Kupatt C et al. An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J. Clin. Invest. 2003 111 : 1665 1672.
31. Shaykhiev R, Beisswenger C, Kandler K et al. Human endogenous antibiotic LL-37 stimulates airway epithelial cell proliferation and wound closure. Am. J. Physiol. Lung Cell Mol. Physiol. 2005 289 : L842 8.
32. Cote CG, Celli BR. BODE index: a new tool to stage and monitor progression of chronic obstructive pulmonary disease. Pneumonol. Alergol. Pol. 2009 77 : 305 313.
33. Puhan MA, Garcia-Aymerich J, Frey M et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009 374 : 704 711.
34. Bourbeau J, Christodoulopoulos P, Maltais F et al. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007 62 : 938 943.
35. Powrie DJ, Wilkinson TM, Donaldson GC et al. Effect of tiotropium on sputum and serum inflammatory markers and exacerbations in COPD. Eur. Respir. J. 2007 30 : 472 478.